Given the importance of VEGF in the pathology of RA, antiangiogenic therapies, particularly those involving an anti-Flt-1 blocking agents, could when administered as a monotherapy or in combination with other biologic agents selectively ameliorate RA symptoms and reverse its fundamental pathology. Here, VEGFA is linked to rheumatoid arthritis.